ArticleCancer research2007
Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth.
Article in Cancer research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- NFKB1 -94insertion/deletion ATTG polymorphism and cancer risk: Evidence from 50 case-control studies.Oncotarget · 2017Pooled it
- Targeting noncanonical nuclear factor kappa B signalling in CYLD cutaneous syndrome by selective inhibition of IκB kinase alpha.The British journal of dermatology · 2026Article
- Identification of GDP as a small inhibitory molecule in HepG2 cells by non‑targeted metabolomics analysis.Oncology letters · 2025Article
- Review
- A Review: Mechanism ofEvidence-based complementary and alternative medicine : eCAM · 2021Review
- IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.Lung cancer (Amsterdam, Netherlands) · 2019Article
- Plasmodium circumsporozoite protein suppresses the growth of A549 cells via inhibiting nuclear transcription factor κB.Oncology letters · 2018Article
- The Role of Melanoma Cell-Stroma Interaction in Cell Motility, Invasion, and Metastasis.Frontiers in medicine · 2018Review
- Current position of TNF-α in melanomagenesis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα.Cancer discovery · 2014Article
- The Plasmodium circumsporozoite protein, a novel NF-κB inhibitor, suppresses the growth of SW480.Pathology oncology research : POR · 2012Article
- Association of an NFKB1 intron SNP (rs4648068) with gastric cancer patients in the Han Chinese population.BMC gastroenterology · 2012Article
- Article
- Inhibitory kappa B Kinases as targets for pharmacological regulation.British journal of pharmacology · 2012Review
- Article
- Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS).Genes & development · 2011Article
- Conditional ablation of Ikkb inhibits melanoma tumor development in mice.The Journal of clinical investigation · 2010Article
- Nuclear factor-κB expression is predictive of overall survival in patients with cutaneous melanoma.Oncology letters · 2010Article
- Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis.Cancer research · 2010Article
- Inside life of melanoma cell signaling, molecular insights, and therapeutic targets.Current oncology reports · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Constitutive activation of nuclear factor-kappaB (NF-kappaB) has been directly implicated in tumorigenesis of various cancer types, including melanoma. Inhibitor of kappaB kinase (IKK) functions as a major mediator of NF-kappaB activation. Thus, development of an IKK-specific inhibitor has been a high priority, although it remains unclear whether systemic inhibition of IKK will provide therapeutic benefit. In this study, we show that inhibition of NF-kappaB activity in melanocytes that are persistently expressing an active H-Ras(V12) gene and are deficient in the tumor suppressors inhibitor A of cyclin-dependent kinase 4/alternative reading frame results in reduction of melanoma tumor growth in vivo. This effect is, at least in part, via regulation of NF-kappaB nuclear activation and RelA phosphorylation. Based on this result, we developed a double hammerhead ribozyme long-term expression system to silence either IKKalpha or IKKbeta. The ribozymes were placed in an EBV construct and delivered i.v. to nude mice bearing melanoma lesions, which developed after i.v. injection of H-Ras-transformed melanoma cells. Our in vivo data show that knockdown of endogenous IKKbeta significantly reduces the growth of the melanoma lesions and knockdown of either IKKalpha or IKKbeta prolongs the life span of immunocompetent mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.